The ability of various in vitro methods of antibiotic susceptibility testing to predict therapeutic outcome in patients infected with Mycobacterium avium complex (MAC) was evaluated. Pretreatment bloodstream MAC isolates from 38 patients with AIDS, previously treated in a randomized fashion with either ethambutol, rifampin, or clofazimine, were tested by three conventional methods using broth or agar, as well as by cocultivation with macrophages. The results obtained with each method were compared with the quantitatively determined bacteriologic response to the administration of the single agent in humans. None of the conventional in vitro susceptibility methods was predictive of therapeutic outcome, while the results of cocultivation with macrophages were of moderate predictive value. The positive predictive value of a response in humans based on a response in macrophages (defined by~1.0 log reduction in baseline colony counts after 5 days of treatment) was 74%. The negative predictive value was 82%.
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The evaluation of in vitro susceptibility to antimicrobial agents is central to both new drug development and the clinical management of patients with infectious diseases. However, this centrality depends on the assumption that in vitro susceptibility test results are predictive of therapeutic outcome. The predictive value of such results is now accepted for most bacterial infections, including those due to Mvcobacterium tuberculosis. However, data are inadequate to demonstrate the relevance of in vitro susceptibility results (or of results in therapeutic animal models of infection) to outcome oftreatment of Mycobacterium avium complex (MAC) infection in humans.
On the basis of the relative antimicrobial resistance of this organism to conventional antimycobacterial agents and concern about the emergence of resistance during therapy, the treatment of MAC infection has generally involved the administration of multiple drugs in combination. This practice has made highly problematic any attempt to correlate therapeutic outcome with the results of susceptibility studies. Further complicating such attempts is the use of several different susceptibility test methods by individual laboratories. In summary, the multiplicity of susceptibility methods and the routine polypharmaceutical approach to the treatment of patients with MAC infection have precluded a systematic analysis of the therapeutic predictive value of susceptibility test results in this infection.
We recently reported the results of a randomized trial designed to determine the individual quantitative antimycobacterial effects of three drugs (ethambutol, clofazimine, and rifampin) in AIDS patients with MAC bacteremia [1] . In this study, patients were randomized to receive one of these drugs for 4 weeks, and bacteriologic response was determined by measuring the effect on the level of mycobacteremia. This study provided the opportunity to rigorously and quantitatively evaluate the relevance of in vitro susceptibility testing, by multiple methods, to the antibacterial effect of these drugs when administered to humans.
Methods
Clinical isolates. Sixty patients who had at least one blood culture positive for MAC and who had not received antimycobacterial therapy were enrolled in the clinical study between August 1990 and August 1991 [I] . Patients were randomized to receive ethambutol (800 mg), rifampin (600 mg), or clofazimine (200 mg) daily for 4 weeks. Patients were considered evaluable with regard to bacteriologic response if they had a positive quantitative mycobacteriologic blood culture at entry to study and a quantitative rm 1996;173 (March) blood culture at week 4 and if they had received at least 50% of the assigned study drug for 4 weeks. The change at week 4 in colony counts (log., change in cfu/mL) relative to the pretreatment value was determined for each subject. The lysis centrifugation method (Isolator; Wampole Laboratories, Cranbury, NJ) for quantitation of MAC blood colonies was used as described [2, 3] . Patients were classified as responders if their colony count decreased from baseline or as nonresponders if there was no change or an increase from baseline. Pretreatment isolates were stored and transported using Lowenstein-Jensen or 7H I0 agar medium. Fortyone evaluable patients completed the 4-week study, but only 38 viable isolates were available. Transparent colonies were selected and stored at -70°C in 7H9 broth.
Susceptibility methods. Ethambutol (Lederle Laboratories, Pearl River, NY) was dissolved to a final concentration of 1280 J.lg/mL. Rifampin (CIBA-GEIGY, Suffern, NY) was dissolved in methanol and diluted with distilled water to a final concentration of 1280 J.lg/mL for storage. Clofazimine (CIBA-GEIGY) was dissolved in dimethyl sulfoxide to achieve a concentration of 210 J.lg/mL.
The broth-and agar-based in vitro susceptibility tests were done at pH 6.6-6.8 in duplicate. The agar dilution method followed the procedure defined by the National Committee for Clinical Laboratory Standards [4] with one exception: 7Hll agar supplemented with oleic acid, albumin fraction 5, dextrose, and catalase was used. The final concentrations of the drugs used were as follows: ethambutol, 0.5, 1,2,4, 8, and 16 J.lg/mL; rifampin, 0.5, I, 2, 4, 8, and 16 J.lg/mL; and clofazimine, 0.0625, 0.125, 0.25, 0.5, 1, and 2 J.lg/mL. A suspension of isolates was made in Middlebrook 7H9 broth and diluted to contain 2.0 X 10' cfu/mL. Each quadrant was inoculated with 50 J.lL of the suspension. The plates were incubated at 37°C and examined after 21 days. If the control quadrant had~100 colonies, the test was considered valid. If there was no growth in a drug-containing quadrant after 21 days, the strain was considered susceptible to that concentration. The MIC was defined as the lowest concentration of drug that completely inhibited 99% of MAC growth.
Broth microdilution studies were done as described using an inoculum of 100 J.lL of a 10 5 cfu suspension [5] . The final concentrations of the drugs were as follows: ethambutol, 0.5-128.0 J.lg/ mL; rifampin, 0.5-128.0 J.lg/mL; and clofazimine, 0.0625-16.0 J.lg/mL. MIC determinations were done after 7 days of incubation. The MIC was defined as the lowest concentration of antimicrobial agent producing no visible growth. The MBC was defined as the lowest concentration of drug that killed at least 99% of the original inoculum.
Radiometric susceptibility testing was done as described, using BACTEC 12B media (Becton Dickinson Diagnostic Instrument Systems, Towson, MD) [6] . The final concentrations used were as follows: ethambutol, 1,2,4,8, and 16 J.lg/mL; rifampin, 1,2,4, 8, and 16 J.lg/mL; and clofazimine, 0.125, 0.25, 0.5, and I J.lg/mL. The 12B vials were read daily for 8 days. The MIC end point was defined as the lowest concentration of drug that produced a growth index "S50 on day 7 or 8 and showed no visible growth. The final inoculum was~lOs/mL.
Cocultivation with macrophages. The effects of the individual agents, each at a single concentration, against intracellular MAC were determined by cocultivation with monocyte-derived macrophages obtained from a normal volunteer as described [7, 8] . The results obtained were compared with the growth of bacteria in the control culture (untreated macrophages) at days 0 and 5. An intracellular bactericidal response was defined as a reduction in the viable bacterial colony counts in the test sample by~I logarithmic unit compared with those of the baseline control specimen before drug addition. A nonresponse was considered to be a change of < 1 logarithmic unit. An intracellular bacteriostatic effect was defined as a reduction of viable bacterial counts at day 5 by~1 logarithmic unit compared with the control at day 5. Pearson correlation was used to assess the degree of bacteriostatic and bactericidal response in macrophages with the degree of bacteriologic response in humans.
Statistical analyses. Susceptibility testing was done on the clinical isolates by the laboratory staff blinded to the clinical and bacteriologic results in humans. Pearson correlation was used to assess quantitative bacteriologic response and susceptibility results. The mean MICs of the isolates obtained from responders versus nonresponders were compared using the Wilcoxon twosample test. Fisher's exact test was used to correlate the categorical patient response with the results of susceptibility testing and the categorical response in macrophages.
Results

Antibacterial effect of individual agents in humans.
Of the three agents studied, ethambutol had the greatest antibacterial effect in humans [I] . In the 38 patients from whom a pretreatment isolate was available for susceptibility testing, the mean change (:!::SD) in baseline colony counts after 4 weeks of ethambutol was -0.4 :!:: 0.7 10glO cfu/mL (range, -1.5 to 1.3). In contrast, mean changes in baseline colony counts were -0.1 :!:: 0.8 10glO cfu/mL (range, -1.4 to 1.0) and 0.1 :!:: 0.6 10glO cfu/ mL (range, -1.0 to 0.9) for patients who received clofazimine and rifampin, respectively. Nine (75%) of 12 patients who received ethambutol, 7 (58%) of 12 who received c1ofazimine, and 6 (43%) of 14 who received rifampin were responders.
Agar, broth microdilution, and BACTEC methods. The mean geometric MICs of isolates from responders and nonresponders were compared for each of the three conventional susceptibility methods (table 1). Although there was no apparent statistically significant difference between the 2 groups, the MICs of the isolates from responders were generally lower (~I dilution) than those from nonresponders for each of the methods.
MICs obtained by agar, broth microdilution, and radiometric dilution were plotted against the bacteriologic response for each drug ( figure I ). There was no apparent linear correlation between the degree of individual bacteriologic response and the MIC of the isolate obtained from the same individual susceptibility test result (R = .0, .12, and .04 for agar, broth, and BACTEC methods, respectively; P~.48). There was also no apparent statistically significant association between the mean MBC or MBC/MIC ratio obtained by broth micro dilution and bacteriologic response in humans (data not shown).
The MICs obtained by each method were analyzed according to their susceptibility as defined by a classification proposed by Heifets [9] (based on that used with M. tuberculosis) (table  2) . The values used to indicate susceptibility are ,,;:4 {Lg/mL for both rifampin and ethambutol and ,,;:0.25 {Lg/mL for c1ofazi-mine, Among the responders to ethambutol, 1 (11%) of 9 isolates was susceptible by the agar method, but 5 (56%) were susceptible by both broth microdilution and radiometric BACTEC methods. For rifampin responders, 33% of the isolates were susceptible by agar, but 67% were susceptible by the broth method and 50% by BACTEC. For clofazimine responders, none of the isolates were susceptible by agar, but 43% were susceptible by the broth microdilution and BACTEC methods.
From the 3 patients who did not respond to ethambutol at 4 weeks, 1 isolate was susceptible to ethambutol by both the broth and BACTEC methods. For the 8 patients who did not respond to rifampin at 4 weeks, 75% and 37% of their isolates were susceptible by the broth and BACTEC methods, respectively. Of the 5 patients who did not respond to clofazimine at 4 weeks, 20% and 40% were considered susceptible to clofazimine using the broth and BACTEC methods, respectively. However, none of the isolates obtained from any of the nonresponders to the three drugs was susceptible as determined using the agar method.
Cocultivation with macrophages. All three agents were bacteriostatic against MAC within macrophages. Relative to that of the untreated controls at day 5, mean colony counts were 1.3 ± 0.6 log., cfu/mL lower for rifampin (n = 14), 1.2 ± 0.5 10gIO cfu/mL lower for ethambutol (n = 12), and 1.0 ± OJ 10gIO cfu/mL lower for clofazimine (n = 12).
There was a significant linear correlation (R = .70, P = .01) between the bacteriostatic response in macrophages and the degree of bacteriologic response in humans for clofazimine (n = 12) (figure 2). In 6 cases, clofazimine caused a bacteriostatic response in macrophages and a bacteriologic response in the corresponding humans (table 3) . The odds ratio of a response in humans based on a response in macrophages was 24 (95% confidence interval [CI], 0.73-4264; P = .04). No apparent statistically significant linear relationship was observed for ethambutol (R = .19, P = .56, n = 12), although a trend was evident for rifampin (R = .48, P = .08, n = 14). The odds ratio was 5.0 (95% CI, 0.3-179; P = .24) for rifampin (table  3) . When the data for the three agents were pooled, the odds ratio was 12.9 (95% CI, 1.8-115.0; P = .002). Twenty (74%) of 27 isolates that showed a bacteriostatic response in macrophages also showed a bacteriostatic response in humans, and 9 (82%) of II isolates that failed to respond in macrophages had no response in humans. NOTE. Response is defined as reduction in pretreatment colony counts in 10 mL of blood after 4 weeks of treatment. Nonresponse is defined as increase or no change in colony count after 4 weeks of therapy. Dotted line indicates cutoff for susceptibility: ,,;4 J.Lg/mL for ethambutol and rifampin and ,,;25 J.Lg/mL for clofazimine.
Although overall, bactericidal effects were observed in vitro in 9 instances, no agent demonstrated a mean bactericidal effect. Colony counts rose, relative to controls at baseline, a mean of 0.44 ::J:: 0.6, 0.20 ::J:: 0.4, and 0.66 ::J:: 0.6 log., cfu/mL for rifampin, ethambutol, and clofazimine, respectively.
There was no apparent linear correlation between the degree of bactericidal response in macrophages and the degree of bacteriologic response in humans for any of the individual agents (all cases, P~.2). When the data for all three agents were combined, 8 (89%) of 9 isolates against which a bactericidal response in macrophages was demonstrated had been obtained from patients in whom a bacteriologic response to treatment had been observed. The odds of a bacteriologic response in humans based on a bactericidal response in macrophages was 8.6 (95% CI, 0.86-207; P = .03). Of the 29 isolates that failed to show a bactericidal response within macrophages, 15 (52%) were obtained from human nonresponders.
Discussion
Despite the remarkable efficacy of the macrolides in the treatment of MAC infection, not all patients fully benefit from therapy. Recrudescence of infection, often associated with high-level resistance to clarithromycin, is frequent when this agent is used alone [10] . A consensus committee has therefore recommended that patients with AIDS and disseminated MAC infection be treated with either clarithromycin or azithromycin plus at least one other drug, [11] preferably ethambutol or clofazimine. This recommendation was based, in part, on the clinical trial that provided the basis for the work reported herein [1] . Ongoing studies are addressing the issue of which drug or drugs are optimal for coadministration with the macrolides as well as which are useful for patients with clarithromycin-resistant disease.
Our work was done to determine whether commonly used methods of susceptibility testing of MAC provide relevant and useful information for the selection of optimal antimycobacterial therapy. Studies have previously attempted to address this question but unfortunately were limited by the use of only a single method of susceptibility testing and the multiplicity of simultaneously administered antimicrobial agents.
Some studies have been interpreted to suggest a correlation between the clinical and mycobacterial response of humans infected with MAC and the results of susceptibility studies. In Change in baseline colony counts (log10 cfu/mL) in humans a retrospective study by Horsburgh et al. [12] , 75 patients with pulmonary MAC infection received a combination of six or more drugs for at least 4 months. Patients who responded (based on 3 consecutive culture-negative respiratory specimens) received more drugs to which their isolate was susceptible than did those patients who did not respond to therapy (2.4 vs. 1.4 agents). In a prospective clinical study, Tsukamura [13] found a correlation between the results of susceptibility studies and successful eradication of MAC in sputa in patients with pulmonary MAC disease, each treated with multiple agents. Patients with a successful response to therapy had organisms with lower MICs to the agents they had received. Others have failed to identify a relationship between antimycobacterial response in humans and the results of susceptibility studies. Gordon et al. [14] studied 27 human immunodeficiency virus-infected patients with MAC bacteremia who received a combination of ciprofloxacin, rifampin, clofazimine, and ethambutol. There was no significant difference in the MICs of the pretreatment isolates, as determined by the radiometric method, between those patients in whom bacteremia was successfully cleared and those who did not respond to therapy. Masur et al. [15] also did not find a correlation between the results of in vitro susceptibility testing (using agar) and clearance of mycobacteremia in patients with AIDS who received a combination of clofazimine and rifabutin.
One characteristic of the drugs used in these studies, as well as in the study reported here, is that they are, at best, weakly bacteriostatic against MAC. In addition, they appear to have a unimodal distribution of MICs. Susceptibility testing with clarithromycin, on the other hand, appears to define a bimodal population of isolates: either very susceptible (MIC <4 p,g/ mL) or highly resistant (MIC >32 p,g/mL). While 99% of the 152 pretreatment isolates in a trial in which patients received clarithromycin alone [10] were susceptible to clarithromycin at low concentrations, 46% of the posttreatment isolates in patients who relapsed had MICs >32 p,g/mL. Thus, the posttreatment microbial isolates demonstrated a biphasic population consistent with a single-step mutation leading to high-level resistance. It is likely that with drugs with such highly dichotomous results, in vitro susceptibility testing is reasonably predictive of outcome of therapy. However, the unimodal, relatively narrow range of susceptibility found with such agents as rifampin, ethambutol, and clofazimine militates against these tests having such discriminatory power.
Another important factor that may preclude a predictive role for broth and agar methods of susceptibility testing of MAC isolates is that these methods fail to take into account the intracellular location of the organism in the infected host. However, the method using cocultivation with macrophages takes this factor into consideration and provides a test of the ability of an antimicrobial agent to penetrate the lipid membrane of the phagocytic cell and to remain active within the intracellular milieu. Uptake into macrophages has been demonstrated for rifampin, ethambutol, and clofazimine [16] . Rifampin has been shown to have cellular/extracellular ratios of 3-5, while ratios of 1-10 have been reported for ethambutol. Clofazimine pene-
